Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of LP-005 injection in moderate to severe periodontitis
CTR20261509Phase 2Active
- Sponsor
- LongBio Pharma
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in periodontitis, sponsored by LongBio Pharma. Started Apr 2026; status: active.
02
Drugs
LP-005
03
Conditions
periodontitis
Beyond the preview
Go deeper on CTR20261509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261509.